US 12,213,999 B2
Compositions and methods for treating type 1 and type 2 diabetes and related disorders
Ronald M. Evans, La Jolla, CA (US); Eiji Yoshihara, La Jolla, CA (US); Michael R. Downes, La Jolla, CA (US); Ruth T. Yu, La Jolla, CA (US); and Annette R. Atkins, La Jolla, CA (US)
Assigned to SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA (US)
Filed by SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA (US)
Filed on Jan. 5, 2021, as Appl. No. 17/141,327.
Application 17/141,327 is a division of application No. 15/359,432, filed on Nov. 22, 2016, granted, now 10,912,800.
Application 15/359,432 is a division of application No. 14/793,391, filed on Jul. 7, 2015, granted, now 9,546,379, issued on Jan. 17, 2017.
Application 14/793,391 is a continuation of application No. PCT/US2015/022799, filed on Mar. 26, 2015.
Claims priority of provisional application 62/105,545, filed on Jan. 20, 2015.
Claims priority of provisional application 62/065,537, filed on Oct. 17, 2014.
Claims priority of provisional application 61/971,308, filed on Mar. 27, 2014.
Prior Publication US 2021/0283187 A1, Sep. 16, 2021
Int. Cl. A61K 35/35 (2015.01); A61K 35/12 (2015.01); A61K 35/39 (2015.01); A61K 35/51 (2015.01); A61K 35/545 (2015.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C07K 14/72 (2006.01); C12N 5/071 (2010.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)
CPC A61K 35/39 (2013.01) [A61K 35/12 (2013.01); A61K 35/35 (2013.01); A61K 35/51 (2013.01); A61K 35/545 (2013.01); A61K 48/00 (2013.01); C07K 14/70567 (2013.01); C07K 14/721 (2013.01); C12N 5/0676 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2501/105 (2013.01); C12N 2501/115 (2013.01); C12N 2501/392 (2013.01); C12N 2501/415 (2013.01); C12N 2506/02 (2013.01); C12N 2510/00 (2013.01); C12N 2710/10032 (2013.01); C12N 2710/10043 (2013.01)] 20 Claims
 
1. A method of treating and/or ameliorating type 1 or type 2 diabetes in a mammalian subject having or suspected of having type 1 or type 2 diabetes, the method comprising:
administering to the mammalian subject an effective amount of glucose-responsive mammalian adipose derived β-like cells, which overexpress recombinant estrogen-related receptor gamma (ERRγ) and pancreatic and duodenal homeobox 1 (PDX1); and
reducing or normalizing blood glucose levels in the subject following administration of the glucose-responsive mammalian adipose derived β-like cells, thereby treating and/or ameliorating type 1 or type 2 diabetes in the subject.